Acadia Pharma (ACAD) Tops Q1 EPS by 12c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.32 +6.75%
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +11.8%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.44), $0.12 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $47.06 million.
- ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
- KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
